MX2016006622A - Metodos para tratar actividad muscular anormal. - Google Patents
Metodos para tratar actividad muscular anormal.Info
- Publication number
- MX2016006622A MX2016006622A MX2016006622A MX2016006622A MX2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A MX 2016006622 A MX2016006622 A MX 2016006622A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating abnormal
- muscular activity
- abnormal muscular
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000003387 muscular Effects 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907675P | 2013-11-22 | 2013-11-22 | |
| PCT/US2014/066740 WO2015077520A1 (en) | 2013-11-22 | 2014-11-21 | Methods of treating abnormal muscular activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006622A true MX2016006622A (es) | 2016-12-09 |
Family
ID=53180159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006622A MX2016006622A (es) | 2013-11-22 | 2014-11-21 | Metodos para tratar actividad muscular anormal. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160303110A1 (OSRAM) |
| EP (1) | EP3071565A4 (OSRAM) |
| JP (1) | JP2017503756A (OSRAM) |
| CA (1) | CA2930167A1 (OSRAM) |
| HK (1) | HK1224294A1 (OSRAM) |
| IL (1) | IL245538A0 (OSRAM) |
| MX (1) | MX2016006622A (OSRAM) |
| WO (1) | WO2015077520A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2930744A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| EP2918266A1 (en) * | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| IL288712B2 (en) | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
| WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
| US10786202B2 (en) | 2016-09-28 | 2020-09-29 | International Business Machines Corporation | Quantifying grip strength and characterizing movement idioms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7367953B2 (en) * | 2003-11-26 | 2008-05-06 | Ge Medical Systems Global Technology Company | Method and system for determining a period of interest using multiple inputs |
| BRPI0708071A8 (pt) * | 2006-02-17 | 2017-12-26 | Birds Pharma Gmbh Berolina Innovative Res & Development Services | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos |
| BRPI0711481A8 (pt) * | 2006-05-02 | 2017-11-28 | Univ Michigan Regents | derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| KR101742668B1 (ko) * | 2008-06-12 | 2017-06-01 | 골지 피티와이 리미티드 | 운동부족 및/또는 운동과잉 상태의 검출 |
| US11016104B2 (en) * | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| EP3345905B1 (en) * | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9676810B2 (en) * | 2010-07-08 | 2017-06-13 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| US9901564B2 (en) * | 2012-03-23 | 2018-02-27 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders |
-
2014
- 2014-11-21 CA CA2930167A patent/CA2930167A1/en not_active Abandoned
- 2014-11-21 JP JP2016533116A patent/JP2017503756A/ja active Pending
- 2014-11-21 MX MX2016006622A patent/MX2016006622A/es unknown
- 2014-11-21 WO PCT/US2014/066740 patent/WO2015077520A1/en not_active Ceased
- 2014-11-21 HK HK16112663.3A patent/HK1224294A1/zh unknown
- 2014-11-21 EP EP14864919.7A patent/EP3071565A4/en not_active Withdrawn
- 2014-11-21 US US15/037,465 patent/US20160303110A1/en not_active Abandoned
-
2016
- 2016-05-08 IL IL245538A patent/IL245538A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL245538A0 (en) | 2016-06-30 |
| EP3071565A4 (en) | 2017-08-02 |
| WO2015077520A1 (en) | 2015-05-28 |
| JP2017503756A (ja) | 2017-02-02 |
| CA2930167A1 (en) | 2015-05-28 |
| US20160303110A1 (en) | 2016-10-20 |
| HK1224294A1 (zh) | 2017-08-18 |
| EP3071565A1 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
| MX2016006622A (es) | Metodos para tratar actividad muscular anormal. | |
| EP2981209A4 (en) | SYSTEM AND METHOD FOR MONITORING PHYSIOLOGICAL CHARACTERISTICS | |
| EP3050043A4 (en) | Monitoring and treating sleep disorders | |
| PL2996737T3 (pl) | Urządzenie i sposób dostarczania parametrów zabiegu do wykonywania zabiegu u pacjenta | |
| SG11201508997RA (en) | Monitor and system for monitoring living organisms | |
| EP2717758A4 (en) | DATA-CAPABLE BAND FOR MEDICAL DIAGNOSTICS, MONITORING AND TREATMENT | |
| EP2990972A4 (en) | TELEMEDICINE SYSTEM FOR REMOTE CONSULTATION, DIAGNOSIS AND MEDICAL TREATMENT SERVICES | |
| PT3027600T (pt) | Derivados de piridazina 1,4-dissubstituídos e a sua utilização para tratamento de condições relacionadas com deficiência em smn | |
| EP2967974A4 (en) | SYSTEMS AND METHODS FOR PROVIDING AUTOMATED TITRATION FOR ORAL APPARATUS THERAPY | |
| SG11201509905PA (en) | Medical/Care Support Method, Medical/Care Support System, And Medical/ Care Support Program | |
| GB2528137B (en) | Wearable activity monitoring device and related method | |
| GB2513585B (en) | Data transfer of a heart rate and activity monitor arrangement and a method for the same | |
| EP3185942A4 (en) | Diagnosis, monitoring, and treatment of respiratory disorders | |
| PT2854870T (pt) | Método e aparelho para a produção de chumbo 212 para uso médico¿ | |
| PT2810599T (pt) | Sistema de estimulação elétrica para o tratamento da apneia do sono | |
| EP3082596A4 (en) | System and method for monitoring physiological activity of a subject | |
| EP3086846A4 (en) | Diagnosing and treating alzheimer's disease | |
| SG11201508501QA (en) | Ecg monitor with an implantable part | |
| EP3075305A4 (en) | Auxiliary monitoring alarm method and medical external device using method | |
| SG11201507222WA (en) | Non-woven face mask and corresponding cosmetic treatment method. | |
| GB201309645D0 (en) | Treatment of peripheral arterial disease and other conditions, and apparatus therefor | |
| GB201307728D0 (en) | Heart rate and activity monitor arrangement and a method for using the same | |
| GB2537432B (en) | Battery monitor and monitoring method | |
| EP3020213A4 (en) | A method and a device for monitoring a human brain's sub- cognitive activity using oto-acoustic emissions |